Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4447168
Max Phase: Preclinical
Molecular Formula: C42H70N6O27
Molecular Weight: 1091.04
Molecule Type: Unknown
Associated Items:
ID: ALA4447168
Max Phase: Preclinical
Molecular Formula: C42H70N6O27
Molecular Weight: 1091.04
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@H]1[C@H](OCCCCCCN=[N+]=[N-])O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO[C@]3(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O3)[C@H](O)[C@H](O[C@]3(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O3)[C@H]2O)[C@@H]1O
Standard InChI: InChI=1S/C42H70N6O27/c1-16(52)45-25-19(55)10-41(39(64)65,73-34(25)28(59)21(57)12-49)69-15-24-30(61)36(75-42(40(66)67)11-20(56)26(46-17(2)53)35(74-42)29(60)22(58)13-50)32(63)38(71-24)72-33-23(14-51)70-37(27(31(33)62)47-18(3)54)68-9-7-5-4-6-8-44-48-43/h19-38,49-51,55-63H,4-15H2,1-3H3,(H,45,52)(H,46,53)(H,47,54)(H,64,65)(H,66,67)/t19-,20-,21+,22+,23+,24+,25+,26+,27+,28+,29+,30-,31+,32+,33+,34+,35+,36-,37+,38-,41+,42-/m0/s1
Standard InChI Key: UMRBYFDLUVHLHW-PYIFUAMMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1091.04 | Molecular Weight (Monoisotopic): 1090.4289 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Wu HR, Anwar MT, Fan CY, Low PY, Angata T, Lin CC.. (2019) Expedient assembly of Oligo-LacNAcs by a sugar nucleotide regeneration system: Finding the role of tandem LacNAc and sialic acid position towards siglec binding., 180 [PMID:31351394] [10.1016/j.ejmech.2019.07.046] |
Source(1):